All In Biotech

Drug Trial Radar · NCT01470118

A Study to Evaluate the Duration of LASTACAFT® in Acute Allergic Conjunctivitis

Last checked: Nov 20, 2026Latest source record: Feb 21, 2013 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 127 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

127

Actual

Start

Oct 2011

Primary completion

Dec 2011

Study completion Dec 2011

Sponsor

Lead sponsor
AllerganAbbVie (ABBV)
Sponsor type
Industry
First posted
Nov 11, 2011

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 10 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study will evaluate the duration of action of LASTACAFT® and Pataday™ as compared to artificial tears (placebo) in the prevention of ocular itching associated with allergic conjunctivitis.

Conditions

  • Conjunctivitis, Allergic

Interventions

  • alcaftadine 0.25% ophthalmic solutionDrug

    One drop of alcaftadine 0.25% ophthalmic solution instilled in each eye at Day 0 and Day 14.

  • olopatadine 0.2% ophthalmic solutionDrug

    One drop of olopatadine 0.2% ophthalmic solution instilled in each eye at Day 0 and Day 14.

  • dextran 70 0.1%/hydroxypropyl methylcellulose 0.3%Drug

    One drop of placebo instilled in each eye at Day 0 and Day 14.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Ocular Itching Evaluated by the Subject at 3, 5, and 7 Minutes Post Challenge on Day 0 at Hour 16Time frame: Day 0 Hour 16
  2. Ocular Itching Evaluated by the Subject at 3, 5, and 7 Minutes Post Challenge on Day 14 at Hour 24Time frame: Day 14 Hour 24

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Site not named

    Philadelphia, Pennsylvania

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.